Key result
First-line antihypertensive classes show comparable clinical efficacy, while beta-blockers remain reserved for compelling indications.
Why the study?
This article aimed to analyze the comparative clinical efficacy of modern antihypertensive drug classes and fixed-combination therapy using data from meta-analyses, systematic reviews, and international guidelines published in 2023-2026.
Do modern classes of antihypertensive drugs (ACE inhibitors, ARBs, CCBs, thiazide/thiazide-like diuretics, and beta-blockers) differ in improving blood pressure and reducing stroke, myocardial infarction, and all-cause mortality in patients with arterial hypertension?
Do modern classes of antihypertensive drugs (ACE inhibitors, ARBs, CCBs, thiazide/thiazide-like diuretics, and beta-blockers) differ in improving blood pressure and reducing stroke, myocardial infarction, and all-cause mortality in patients with arterial hypertension?
ACE inhibitors, ARBs, CCBs, and thiazide/thiazide-like diuretics demonstrate comparable efficacy as first-line therapies for arterial hypertension, whereas beta-blockers should be reserved for specific clinical indications.
Answers are grounded in this paper and cite their sources.
May refine antihypertensive selection; leaves open need for updated head-to-head outcome trials.
This article analyzes the comparative clinical efficacy of modern classes of antihypertensive drugs used in the treatment of arterial hypertension based on data from recent meta-analyses, systematic reviews, and international clinical guidelines (ESH 2023, ACC/AHA) published in 2023–2026. The results concerning the blood pressure-lowering effects of angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), thiazide and thiazide-like diuretics, and beta-blockers, as well as their effects on stroke, myocardial infarction, and all-cause mortality, were summarized. The analysis showed that ACE inhibitors, ARBs, CCBs, and diuretics have approximately comparable efficacy as first-line therapies, whereas beta-blockers are recommended only when specific clinical indications are present.
No takes yet. Share an insight, caveat, or question.
Doniyorbek Pozildinov (2026) conducted a review in Arterial hypertension. ACE inhibitors, ARBs, calcium channel blockers, and thiazide/thiazide-like diuretics vs. Beta-blockers and cross-class comparisons was evaluated on Blood pressure lowering, stroke, myocardial infarction, and all-cause mortality. ACE inhibitors, ARBs, CCBs, and diuretics demonstrate comparable first-line efficacy for hypertension, whereas beta-blockers are reserved for specific clinical indications.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: